Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 66.7%High 1 · 33.3%

Dopamine agonist vs placebo

Withdrawals due to adverse events · patients with restless legs syndrome according to IRLSSG, 18 years or older

Summary of findings: dopamine agonists leads to higher number of dropouts due to adverse events compared with placebo (high certainty).

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
OR 1.82 [1.35, 2.45]
34 studies · 7054 participants
High

Dopamine agonist vs levodopa

Adverse effects (drop‐outs due to adverse effects4) · patients with restless legs syndrome

Summary of findings: dopamine agonists probably leads to higher number of drop outs due to adverse events compared with levodopa (moderate certainty).

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
OR 1.7
3 studies · 504 participants
Moderate

Dopamine agonist vs levodopa

Number of participants reporting an adverse event · patients with restless legs syndrome

Summary of findings: dopamine agonists showed no clear difference in number of patients experiencing adverse events compared with levodopa (moderate certainty).

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
OR 2.87 [0.43, 19]
3 studies · 461 participants
Moderate